Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(145 produits)
- Bcr-Abl(102 produits)
- EGFR(572 produits)
- FAK(72 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- JAK(245 produits)
- PDGFR(126 produits)
- RAAS(86 produits)
- Src(78 produits)
- Syk(38 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(268 produits)
Affichez 6 plus de sous-catégories
1414 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-87
CAS :<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Formule :C28H33N7O2Degré de pureté :98.64%Couleur et forme :SolidMasse moléculaire :499.61KER047
CAS :<p>ALK2-IN-4, a highly effective ALK2 inhibitor.</p>Formule :C26H30FN7ODegré de pureté :98.49% - >99.99%Couleur et forme :SolidMasse moléculaire :475.56IN-1130
CAS :<p>IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).</p>Formule :C25H20N6ODegré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :420.47HM43239
CAS :<p>HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.</p>Formule :C29H33ClN6Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :501.07HER2-IN-21
CAS :<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447VEGFR/PDGFR-IN-1
CAS :<p>VEGFR/PDGFR-IN-1 (Compound 1) is an inhibitor of VEGFR with an IC50 of 0.4 μM. It can inhibit angiogenesis in HUVEC cells and holds promise for impeding tumor growth and metastasis.</p>Formule :C17H21N5O3Couleur et forme :SolidMasse moléculaire :343.38TZEP7
CAS :<p>TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.</p>Formule :C27H19ClFNSCouleur et forme :SolidMasse moléculaire :443.963FGFR1 inhibitor-17
CAS :<p>FGFR1inhibitor-17 (Compound 92) is a potent inhibitor of FGFR1, with promising applications in cancer research.</p>Formule :C16H13ClN2O3Couleur et forme :SolidMasse moléculaire :316.739TrxR/EGFR-IN-1
CAS :<p>TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.</p>Formule :C24H24AuClFN6O2PCouleur et forme :SolidMasse moléculaire :710.878Tyrosine kinase-IN-9
CAS :<p>Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</p>Formule :C20H14ClN3O3Couleur et forme :SolidMasse moléculaire :379.796TGF-βRI inhibitor 3
CAS :<p>TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.</p>Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.396lirucitinib
CAS :<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468LNK01004
CAS :<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57EGFR-IN-147
CAS :<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275VEGFR-2-IN-65
CAS :<p>VEGFR-2-IN-65 (Compound 07) functions as a VEGFR-2 inhibitor. It forms hydrogen bonds with Cys180 and can inhibit tube formation in HUVECs.</p>Formule :C21H18N2O3Couleur et forme :SolidMasse moléculaire :346.379Milpecitinib
CAS :<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463DA-0157
CAS :<p>DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.</p>Formule :C31H43BrN7O2PCouleur et forme :SolidMasse moléculaire :656.597FGFR1 inhibitor-16
CAS :<p>FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.</p>Formule :C16H9N5O3SCouleur et forme :SolidMasse moléculaire :351.339FAK-IN-3
<p>FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.</p>Formule :C28H28N6O4Couleur et forme :SolidMasse moléculaire :512.56FGFR4-IN-7
<p>FGFR4-IN-7 is a covalent, reversible FGFR4 inhibitor (IC50: 0.42 μM) that blocks the FGFR4 signaling pathway, thereby inducing apoptosis.</p>Formule :C26H25Cl2N5O3Couleur et forme :SolidMasse moléculaire :526.41VEGFR-2-IN-13
<p>VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.</p>Formule :C24H18N6O2SCouleur et forme :SolidMasse moléculaire :454.5EGFR-IN-44
<p>EGFR-IN-44: potent EGFR kinase inhibitor, orally active, IC50 4.11 nM, 33.57% bioavailability, induces apoptosis, for lung cancer study.</p>Formule :C27H29ClN6O2SCouleur et forme :SolidMasse moléculaire :537.08DBMB
CAS :<p>DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.</p>Formule :C24H22N4OCouleur et forme :SolidMasse moléculaire :382.458BTK-IN-8
<p>BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).</p>Formule :C26H36N6O3Couleur et forme :SolidMasse moléculaire :480.6FAK-IN-23
CAS :<p>FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).</p>Formule :C32H38F3N5O8Couleur et forme :SolidMasse moléculaire :677.668HSN748
CAS :<p>HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.</p>Formule :C27H24F3N7OCouleur et forme :SolidMasse moléculaire :519.521JBJ-02-112-05
CAS :<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54EGFR-IN-38
CAS :<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96Flonoltinib sulfate
CAS :<p>Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.</p>Formule :C25H36FN7O5SCouleur et forme :SolidMasse moléculaire :565.661TX2-121-1
CAS :<p>TX2-121-1 targets HER3 for proteasome-mediated degradation to inhibit HER3-dependent signalling and growth.</p>Formule :C42H52N8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :716.91CEP-14083
CAS :<p>CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.</p>Formule :C31H30N6O2Couleur et forme :SolidMasse moléculaire :518.61E6201
CAS :<p>E6201, a dual kinase inhibitor, blocks MEK1/FLT3 and has anti-tumor/psoriasis effects with low IC50s: ERK2 (5.2 nM), JNK (91 nM), p38 MAPK (19 nM).</p>Formule :C21H27NO6Couleur et forme :SolidMasse moléculaire :389.44SJ-C1044
CAS :<p>SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.</p>Formule :C25H14F7N7OCouleur et forme :SolidMasse moléculaire :561.41Paeoniflorin-6′-O-benzene sulfonate
CAS :<p>Paeoniflorin-6′-O-benzene sulfonate (CP-25) acts as an inhibitor of G protein-coupled receptor kinase 2 (GRK2), preventing its translocation to the cell membrane and inhibiting the JAK1/STAT3 signaling pathway. It suppresses HaCaT cell proliferation induced by IL-17A/CXCL2. In mouse models, CP-25 reduces the levels of inflammatory cytokines and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3, and CXCL9, thereby alleviating psoriasis induced by Imiquimod.</p>Formule :C29H32O13SCouleur et forme :SolidMasse moléculaire :620.622Protein kinase inhibitor 13
CAS :<p>Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.</p>Formule :C19H20FN5OSCouleur et forme :SolidMasse moléculaire :385.458CGP062464
CAS :<p>CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.</p>Formule :C18H14N4Couleur et forme :SolidMasse moléculaire :286.331HER2-IN-8
CAS :<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Formule :C26H25F2N9O3Couleur et forme :SolidMasse moléculaire :549.53FGFR2/3-IN-2
CAS :<p>FGFR2/3-IN-2 (compound 10) is an orally active inhibitor targeting FGFR2 and FGFR3. It exhibits IC50 values of 3.7 nM for FGFR2 and 31.2 nM for FGFR3, with a pre-incubation time of 1 hour. FGFR2/3-IN-2 demonstrates selectivity over FGFR1/4 and other kinases, and does not cause diarrhea or increased serum phosphate in vivo. In the SNU-16 gastric cancer model, FGFR2/3-IN-2 can induce tumor stasis or regression.</p>Formule :C29H23FN6O3Couleur et forme :SolidMasse moléculaire :522.53EGFR-IN-159
CAS :<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.424Gamendazole
CAS :<p>Gamendazole is a novel drug candidate for male contraception. It has been shown to reduce fertility in male rats without affecting testosterone levels.</p>Formule :C18H11Cl2F3N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :415.19EGFR-IN-149
CAS :<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formule :C16H15N3OSCouleur et forme :SolidMasse moléculaire :297.375M-COPA
CAS :<p>M-COPA disrupts Golgi, blocks MET & Arf1 activation, and inhibits angiogenesis via VEGFR & NF-kB pathways.</p>Formule :C25H34N2O2Couleur et forme :SolidMasse moléculaire :394.55Clifutinib
CAS :<p>Clifutinib (Compound 9e) is an orally active, selective inhibitor of FMS-like tyrosine kinase 3 (FLT3-ITD) with an IC50 of 15.1 nM. It inhibits FLT3-ITD kinase activity and blocks downstream signaling pathways, including RAS/MAPK, PI3K/AKT, and JAK/STAT5. Clifutinib induces apoptosis in FLT3-ITD mutated acute myeloid leukemia (AML) cells and is a potential candidate for research in relapsed/refractory FLT3-ITD positive AML.</p>Formule :C29H34N4O4Couleur et forme :SolidMasse moléculaire :502.605VEGFR-2/DHFR-IN-2
<p>VEGFR-2/DHFR-IN-2 inhibits VEGFR-2 & DHFR (IC50: 0.623 & 9.085 μM), toxic to C26, HepG2, MCF7 cells (IC50: 3.59-8.38 μM), promising for cancer study.</p>Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.4VEGFR-2-IN-15
<p>VEGFR-2-IN-15 (Compound 14b) is a potent inhibitor of VEGFR-2. VEGFR-2-IN-15 inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Formule :C23H18ClN3O4SCouleur et forme :SolidMasse moléculaire :467.92FGFR1 inhibitor-15
CAS :<p>FGFR1inhibitor-15 (Compound 23) is an FGFR1 inhibitor with an IC50 value of 27 μM, useful for tumor research.</p>Formule :C17H13FN4OCouleur et forme :SolidMasse moléculaire :308.31VEGFR-2-IN-17
<p>VEGFR-2-IN-17 (15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM, showing significant antitumor effects.</p>Formule :C21H14ClN3O2Couleur et forme :SolidMasse moléculaire :375.81JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Couleur et forme :SolidBTK-IN-6
<p>BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.</p>Formule :C23H22FN5O3Couleur et forme :SolidMasse moléculaire :435.45Brefeldin A 4-O-nicotinate
CAS :<p>Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.</p>Formule :C22H27NO5Couleur et forme :SolidMasse moléculaire :385.453JAK3/BTK-IN-7
CAS :<p>JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].</p>Formule :C29H30N8O4Couleur et forme :SolidMasse moléculaire :554.6PP487
CAS :<p>PP487 is a dual tyrosine kinase/PI(3)K inhibitor, exhibiting IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. It is applicable in cancer research [1].</p>Formule :C14H14BrN5OCouleur et forme :SolidMasse moléculaire :348.2JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35FGFR-IN-5
CAS :<p>FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.</p>Formule :C25H22N6O3Couleur et forme :SolidMasse moléculaire :454.48EGFR-IN-35
CAS :<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96Pyk2-IN-2
CAS :<p>Pyk2-IN-2 (compound 13j) acts as a Pyk2 inhibitor, exhibiting an IC 50 value of 0.608 μM for FAK kinase [1].</p>Formule :C27H27N7OCouleur et forme :SolidMasse moléculaire :465.55VEGFR-2-IN-12
<p>VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.</p>Formule :C22H24N6O3SCouleur et forme :SolidMasse moléculaire :452.53CDDD11-8
CAS :<p>CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].</p>Formule :C24H26N6Couleur et forme :SolidMasse moléculaire :398.50EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Formule :C28H23N7OCouleur et forme :SolidMasse moléculaire :473.53VEGFR-2/DHFR-IN-1
<p>Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.</p>Formule :C20H18ClNO4Couleur et forme :SolidMasse moléculaire :371.81FLT3/TrKA-IN-1
<p>FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.</p>Formule :C28H30N4O2Couleur et forme :SolidMasse moléculaire :454.56DDO-02267
CAS :<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formule :C18H12N2O7SCouleur et forme :SolidMasse moléculaire :400.362MK-8457
CAS :<p>MK-8457 is a dual inhibitor of SYK and ZAP70, valuable for rheumatoid arthritis research [1].</p>Formule :C24H25F3N4O3SCouleur et forme :SolidMasse moléculaire :506.54EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formule :C16H16N4O2SCouleur et forme :SolidMasse moléculaire :328.39VEGFR-2-IN-25
CAS :<p>VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).</p>Formule :C24H22N6O2Couleur et forme :SolidMasse moléculaire :426.47LT-850-166
<p>LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.</p>Formule :C30H29Cl2N7OCouleur et forme :SolidMasse moléculaire :574.5Sacibertinib
CAS :<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formule :C32H31ClN6O4Couleur et forme :SolidMasse moléculaire :599.08EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98HER2-IN-6
CAS :<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formule :C26H32N8O3Couleur et forme :SolidMasse moléculaire :504.58EG31
CAS :<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25JAK/HDAC-IN-3
CAS :<p>JAK/HDAC-IN-3 (13a), a dual inhibitor of JAK and HDAC, exhibits IC50 values of 25.36 nM for JAK2, 0.2 μM for HDAC, and 0.43 μM for HDAC1, respectively [1].</p>Formule :C28H37FN6O5SCouleur et forme :SolidMasse moléculaire :588.69Tyk2-IN-15
CAS :<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formule :C21H25F2N7OCouleur et forme :SolidMasse moléculaire :429.47EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formule :C30H35FN6O3Couleur et forme :SolidMasse moléculaire :546.64Tyk2-IN-14
CAS :<p>Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].</p>Formule :C22H21N9O2Couleur et forme :SolidMasse moléculaire :443.46EGFR-IN-160
CAS :<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27JAK1/TYK2-IN-4
CAS :<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Formule :C17H23N7OCouleur et forme :SolidMasse moléculaire :341.41Tyk2-IN-17
CAS :<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.42PNU-145156E
CAS :<p>PNU-145156E is a noncytotoxic molecule inhibiting growth and angiogenic factors, suppress tumor angiogenesis, support anti-angiogenic research strategies.</p>Formule :C45H40N10O17S4Couleur et forme :SolidMasse moléculaire :1121.12Lazertinib mesylate
CAS :<p>Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.</p>Formule :C31H38N8O6SMasse moléculaire :650.75CEE321
CAS :<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formule :C18H16ClN5OCouleur et forme :SolidMasse moléculaire :353.806BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Formule :C30H32N6O4Couleur et forme :SolidMasse moléculaire :540.61Ki11502
CAS :<p>Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.</p>Formule :C26H23N3O4SMasse moléculaire :473.54EGFR/HER2-IN-6
<p>EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.</p>Formule :C18H21N5O3SCouleur et forme :SolidMasse moléculaire :387.46FGFR4-IN-6
<p>FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.</p>Formule :C31H33N7O4Couleur et forme :SolidMasse moléculaire :567.64FGFR4-IN-9
<p>FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.</p>Formule :C24H22ClF3N4O4Couleur et forme :SolidMasse moléculaire :522.9EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formule :C27H31ClN7O3PCouleur et forme :SolidMasse moléculaire :568.01E7090 succinate
CAS :<p>E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.</p>Formule :C76H92N10O24Couleur et forme :SolidMasse moléculaire :1529.60Antiallergic agent-1
<p>Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.</p>Formule :C27H19F6N5OCouleur et forme :SolidMasse moléculaire :543.46TTT 3002
CAS :<p>TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.</p>Formule :C27H23N5O3Couleur et forme :SolidMasse moléculaire :465.50JAK2 JH2 binder-1
CAS :<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formule :C29H25N7O6SCouleur et forme :SolidMasse moléculaire :599.62EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formule :C33H28N6O3SCouleur et forme :SolidMasse moléculaire :588.68EGFR-IN-62
<p>EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.</p>Formule :C30H33N9O2Couleur et forme :SolidMasse moléculaire :551.64PF-06463922 acetate
CAS :<p>PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.</p>Formule :C23H23FN6O4Couleur et forme :SolidMasse moléculaire :466.46FGFR1 inhibitor-6
<p>FGFR1 inhibitor-6, IC50: 16.31 nM, blocks cell cycle at pro-G1/G2/M and induces apoptosis.</p>Formule :C27H19N5O4S2Couleur et forme :SolidMasse moléculaire :541.6ALK-IN-23
<p>ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.</p>Formule :C26H29ClN8O3SCouleur et forme :SolidMasse moléculaire :569.08BTK-IN-10
CAS :<p>BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).</p>Formule :C25H24F2N4O2Couleur et forme :SolidMasse moléculaire :450.48VEGFR-2-IN-14
<p>VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Formule :C24H23N3O3SCouleur et forme :SolidMasse moléculaire :433.52NSC381467
CAS :<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34AZD0424
CAS :<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Formule :C25H29ClN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.99Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37
